

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1.-87. (Canceled)

88. (Previously presented) An isolated HLA DRB1*15-binding peptide consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

89. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 88 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.

90. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 88 wherein the isolated peptide is non-hydrolyzable.

91. (Currently amended) ~~An~~ The isolated non-hydrolyzable HLA DRB1*15-binding peptide ~~of claim 90 wherein the isolated peptide is~~ selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond;

wherein the amino acid sequence of the peptide consists of the amino acid sequence set forth as SEQ ID NO:7 with 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

92. (Previously presented) A composition comprising
an isolated MAGE-A1 HLA class I-binding peptide, and
the isolated MAGE-A1 HLA DRB1*15-binding peptide of claim 88,
wherein the HLA class I-binding peptide and the MAGE-A1 HLA DRB1*15-binding
peptide are separate isolated peptides.
93. (Previously presented) The composition of claim 92 wherein the amino acid sequence
selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.
94. (Previously presented) The composition of claim 92 wherein the isolated peptide is
non-hydrolyzable.
95. (Currently amended) A The composition comprising
an isolated MAGE-A1 HLA class I-binding peptide, and
the isolated non-hydrolyzable MAGE-A1 HLA DRB1*15-binding peptide of claim 91,
wherein the HLA class I-binding peptide and the non-hydrolyzable MAGE-A1 HLA
DRB1*15-binding peptide are separate isolated peptides of claim 94 wherein the isolated peptide
is selected from the group consisting of peptides comprising D-amino acids, peptides comprising
a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene
peptide bond, peptides comprising a -psi[CH(CN)NH]- (cyanomethylene)amino peptide bond,
peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a
-psi[CH₂O]- peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.